JPX · 7600.T
Japan Medical Dynamic Marketing, Inc.
¥578-¥9 (-1.53%)
Japan Medical Dynamic Marketing, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.49% below the high.
Loading market information…
JPX · 4579.T · JPY
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
RaQualia Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.45% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
RaQualia Pharma Inc.’s next earnings report is currently expected on Nov 13, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow RaQualia Pharma Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a pharmaceutical company dedicated to the global research and development of innovative drug compounds. Its human therapeutic pipeline features several key candidates. Tegoprazan, designed to treat gastroesophageal reflux disease (GERD), is currently undergoing Phase 1 clinical trials in the United States. Grapiprant is in Phase II development in the U.S. and Phase I in China for pain management; it is also being investigated in Phase I studies in both the U.S. and China for its potential in cancer therapy. Beyond human medicines, RaQualia Pharma develops a range of veterinary products. These include grapiprant for managing osteoarthritis in dogs, a ghrelin receptor agonist aimed at addressing cancer-related anorexia/cachexia syndrome and constipation stemming from spinal cord injury, and ELURA, a medication for combating weight loss in cats suffering from chronic kidney disease. The company's extensive R&D pipeline also covers various other therapeutic areas. This includes a TRPM8 blocker for neuropathic pain, a motilin receptor agonist targeting gastrointestinal motility disorders such as gastroparesis, functional dyspepsia, and post-operative ileus, and a potassium-competitive acid blocker for GERD, which has successfully concluded Phase 1 clinical trials. Further early-stage developments encompass a 5-HT4 partial agonist for gastroparesis, functional dyspepsia, and chronic constipation; a 5-HT2B antagonist for irritable bowel syndrome with diarrhea; EP4 antagonists for canine pain management and, in separate Phase I trials, for cancer and general pain indications; a serotonin 5-HT2A and dopamine D2 receptor blocker for schizophrenia; a Cyclooxygenase-2 inhibitor (Phase I for pain); a CB2 agonist; a selective sodium channel blocker; a P2X7 receptor antagonist (Phase I for neuropathic pain); and a retinoic acid receptor alpha agonist. To further its research and development initiatives, RaQualia maintains strategic partnerships with Interprotein Corporation, ASKA Pharmaceutical Co., Ltd., and Epigeneron, Inc.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:17 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥578-¥9 (-1.53%)
Japan Medical Dynamic Marketing, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.49% below the high.
¥411-¥11 (-2.61%)
Stella Pharma Corporation’s quoted price sits in the lower half of its reported 52-week range, 58.69% below the high.
¥749-¥17 (-2.22%)
CanBas Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 24.42% below the high.
¥2,161+¥63 (+3.0%)
Techno Medica Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 22.46% below the high.
¥418+¥2 (+0.48%)
Daiken Medical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 14.52% below the high.
$1.39-$0.01 (-0.71%)
MediciNova, Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.36% below the high.
¥188-¥7 (-3.59%)
CellSeed Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.66% below the high.
¥149-¥5 (-3.25%)
Kidswell Bio Corporation’s quoted price sits in the lower half of its reported 52-week range, 53.44% below the high.
